Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.

Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest artificial intelligence (AI) supercomputer in the pharmaceutical industry, which it is using to help accelerate the slow process of drug development. If successful, Recursion Pharmaceuticals could deliver outstanding returns to investors. However, there is arguably a far better -- and safer -- way for investors to profit from the potential revolution AI could bring in drug discovery, and that's to invest in Eli Lilly (NYSE: LLY).Image source: Getty Images.Recursion Pharmaceuticals utilizes a proprietary operating system (OS) and an AI-powered algorithm that continuously runs virtual experiments, testing compounds against a library of human genes to predict which ones are most likely to be effective in treating specific diseases. The biotech hopes that its strategy will help improve the success rate of compounds that enter human clinical trials, the majority of which never reach the market.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool